Overview

Olodaterol Bridging Study in Asthma

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The aim of the study is to establish the olodaterol dose in the ethanolic fixed dose combination (FDC) with BI 54903 which is equivalent in bronchodilator effect and systemic exposure to the 5 µg olodaterol reference dose in the aqueous inhalation solution (AIS).

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Olodaterol